Cetuximab treatment in combination with gemcitabine/docetaxel or carboplatin/gemcitabine for chemonaive patients with advanced non-small cell lung cancer (NSCLC): Report on toxicity data from the ongoing Phase II/III GemTax IV study

被引：0
|
作者：
Pilz, L. R. [2 ]
Schmid-Bindert, G. [1 ]
Cicenas, S. [3 ]
Eschbach, C. [4 ]
Kollmeier, J. [5 ]
Kortsik, C. [6 ]
Schumann, C. [7 ]
Serke, M. [8 ]
Steins, M. [9 ]
Manegold, C. [1 ]
机构：
[1] Univ Med Mannheim, Mannheim, Germany
[2] Deutsch Krebsforschungszentrum DKFZ, Heidelberg, Germany
[3] Univ Med Ctr, Vilinius, Lithuania
[4] Asklepios Clin Harburg, Hamburg, Germany
[5] Helios Clin Emil von Behring, Berlin, Germany
[6] Sankt Hildegardis Hosp, Mainz, Germany
[7] Univ Med Ctr, Ulm, Germany
[8] Lung Clin Hemer, Hemer, Germany
[9] Thoraxklin, Heidelberg, Germany
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9 / 10
页数：2
相关论文
共 50 条
  • [1] Cetuximab in combination with gemcitabine/docetaxel or carboplatin/gemcitabine in chemonaive patients with advanced non-small cell lung cancer: toxicity data from an ongoing Phase II/III trial (GemTax IV)
    Schumann, C.
    Pilz, L. R.
    Cicenas, S.
    Eschbach, C.
    Kollmeier, J.
    Kortsik, C.
    Serke, M.
    Steins, M.
    Manegold, C.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 548 - 548
  • [2] Feasibility of cetuximab in combination with gemcitabine or docetaxel or carboplatin/gemcitabine for chemonaive patients with advanced non-small cell lung cancer (NSCLC): Observations from an ongoing randomized phase II/III trial (GemTax IV)
    Pilz, L. R.
    Cicenas, S.
    Eschbach, C.
    Fischer, J. R.
    Kortsik, C.
    Schumann, C.
    Serke, M.
    Steins, M.
    Manegold, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Cetuximab in combination with either sequential gemcitabine followed by docetaxel or with a combination of carboplatin and gemcitabine in chemonaive patients with advanced non-small cell lung cancer (NSCLC): Preliminary toxicity profile from the ongoing phase II/III GemTax IV trial
    Eschbach, Corinna
    Cicenas, Saulius
    Kollmeier, Jens
    Kortsik, Cornelius
    Schumann, Christian
    Serke, Monika
    Steins, Martin
    Manegold, Christian
    Pilz, Lothar R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S287 - S288
  • [4] Cetuximab combined with either gemcitabine (G) followed by docetaxel (D) or carboplatin/gemcitabine (CP/G) in chemotherapy-naive patients (pts) with advanced non-small cell lung cancer (NSCLC): Safety profile from the ongoing phase II/III GemTax IV trial
    Serke, M.
    Pilz, L. R.
    Cicenas, S.
    Eschbach, C.
    Fischer, J.
    Kortsik, C.
    Schumann, C.
    Steins, M.
    Manegold, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)
    Belani, C. P.
    Ramalingam, S.
    Schreeder, M.
    Steis, R.
    Guidice, R.
    Marshland, T.
    Butler, B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Phase I and Pharmacokinetic Study of IV Vinflunine in Combination with Gemcitabine for Treatment of Advanced Non-small Cell Lung Cancer in Chemonaive Patients
    Tournoux-Facon, Caroline
    Senellart, Helene
    Lemarie, Etienne
    Tourani, Jean Marc
    Favrel, Stephanie
    Pouget, Jean Christophe
    Pinel, Marie Claire
    Bennouna, Jaafar
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (07) : 1247 - 1253
  • [7] Combination chemotherapy with carboplatin(CBDCA), docetaxel (DOC) and gemcitabine (GEM) in advanced non-small cell lung cancer (NSCLC). A phase II study
    Pectasides, D
    Aspropotamitis, A
    Halikia, A
    Visvikis, A
    Antoniou, F
    Kalantaridou, A
    Batzios, S
    Karvounis, N
    Athanassiou, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S263 - S263
  • [8] Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC)
    Rubinsak, J. R.
    Spigel, D. R.
    Hainsworth, J. D.
    Webb, C.
    Inhorn, R. C.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Vazquez, E. R.
    Greco, F. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] EGFR-targeting Chimeric Monoclonal IgG-1 Antibody Cetuximab in a Phase II/III Study Added Either to Gemcitabine Followed by Docetaxel or Carboplatin Plus Gemcitabine for Chemonaive Patients With Advanced Non-small Cell Lung Cancer (NSCLC) - Results of the Phase II Study Part
    Kortsik, C.
    Schmid-Bindert, G.
    Pilz, L. R.
    Cicenas, S.
    Eschbach, C.
    Kollmeier, J.
    Schumann, C.
    Serke, M.
    Steins, M.
    Manegold, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S621 - S621
  • [10] Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: A phase II study
    Pectasides, D
    Aspropotamitis, A
    Halikia, A
    Visvikis, A
    Antoniou, F
    Kalantaridou, A
    Karvounis, N
    Batzios, S
    Athanassiou, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) : 3816 - 3821
12345